Brought to you by 
Watson buys Andrx for $1.9bn
09 Nov 2006
Executive Summary
Specialty pharmaco Watson will acquire Andrx (develops generic products using its drug delivery technologies) for about $1.9bn in cash, creating a top- three US generics company. The deal is expected to close in the third quarter of 2006, after which Andrx becomes a wholly owned subsidiary.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Watson buys Andrx for $1.9bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice